Biotech feels a chill from changing U.S. patent rules

摘要

A year after the U.S. Supreme Court issued a landmark ruling that human genes cannot be patented, the bio-tech industry is struggling to adapt to a landscape in which inventions derived from nature are increasingly hard to patent. It is also pushing back against follow-on policies proposed by the U.S. Patent and Trademark Office (USPTO) to guide examiners deciding whether an invention is too close to a natural product to deserve patent protection. Those policies reach far beyond what the high court intended, biotech representatives say.